Actively Recruiting
[C-11]NPA PET-amphetamine in Cocaine Use Disorders
Led by Rajesh Narendran · Updated on 2025-06-05
30
Participants Needed
1
Research Sites
395 weeks
Total Duration
On this page
Sponsors
R
Rajesh Narendran
Lead Sponsor
N
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study uses \[11C\]NPA positron emission tomography (PET) and a d-amphetamine challenge to image amphetamine induced dopamine release in the striatum in subjects with cocaine use disorders (CUD). Amphetamine-induced dopamine release data from this study will be correlated with \[11C\]NOP-1A VT measured at baseline in the midbrain. \[11C\]NOP-1A PET data will be used from aim 1 (see, Study Record: Imaging CRF X NOP interactions in Cocaine Use Disorders)
CONDITIONS
Official Title
[C-11]NPA PET-amphetamine in Cocaine Use Disorders
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Males or females between 18 and 55 years old
- Meet DSM-5 criteria for cocaine use disorder
- No other current DSM-5 psychiatric or addictive disorders
- No current abuse (past 6 months) of opiates, sedative-hypnotics, amphetamines, or MDMA
- No moderate to severe alcohol or cannabis use (more than twice a week)
- Not currently on prescription medical or psychotropic medications
- No current or past severe medical, endocrine, or neurological illnesses including glaucoma, seizure disorders, hypertension, or hypercholesterolemia
- Not currently pregnant or breastfeeding
- No significant radioactivity exposure in past year exceeding guidelines
- No metallic objects in the body contraindicating MRI
- Baseline blood pressure below 140/90 and heart rate below 100
- No first-degree relative with early heart attack or stroke
- No first-degree relative with psychosis or mania
- Completed a baseline [11C]NOP-1A PET scan in Aim 1
You will not qualify if you...
- Presence of other current DSM-5 psychiatric or addictive disorders besides cocaine use disorder
- Current abuse of opiates, sedative-hypnotics, amphetamines, MDMA, or moderate to severe alcohol or cannabis use
- Use of prescription medical or psychotropic medications at screening
- Severe medical, endocrine, or neurological illnesses
- Pregnancy or breastfeeding
- Significant recent exposure to radioactivity beyond guidelines
- Metallic implants or objects contraindicating MRI
- High baseline blood pressure (≥140/90) or heart rate (≥100)
- Family history of early heart attack or stroke
- Family history of psychosis or mania
- Incomplete prior baseline [11C]NOP-1A PET scan in related study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of PIttsburgh
Pittsburgh, Pennsylvania, United States, 15213
Actively Recruiting
Research Team
R
Rajesh Narendran, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here